UBS Group
INTS icon

UBS Group’s Intensity Therapeutics INTS Stock Holding History

UBS Group’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4 Sell
1
-191
-99% -$898 ﹤0.01% 10357
2026
Q1 		$1.13K Sell
192
-824
-81% -$6.73K ﹤0.01% 9614
2025
Q4 		$10.4K Sell
1,016
-4,433
-81% -$45K ﹤0.01% 8222
2025
Q3 		$33.1K Buy
5,449
+5,080
+1,377% +$36.3K ﹤0.01% 7835
2025
Q2 		$2.83K Buy
369
+245
+198% +$5.04K ﹤0.01% 9418
2025
Q1 		$6.1K Buy
124
+3
+2% +$167 ﹤0.01% 8931
2024
Q4 		$5.32K Sell
121
-703
-85% -$51K ﹤0.01% 8677
2024
Q3 		$78.7K Buy
824
+691
+520% +$76.7K ﹤0.01% 6523
2024
Q2 		$16.2K Buy
133
+13
+11% +$1.48K ﹤0.01% 7439
2024
Q1 		$15.7K Buy
120
+100
+500% +$12K ﹤0.01% 7032
2023
Q4 		$4.29K Buy
+20
New +$2.1K ﹤0.01% 7883

Other funds holding INTS

KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

UBS Group's INTS Position: Q2 2026 in Review

UBS Group reduced its Intensity Therapeutics (INTS) stake by 99% in Q2 2026, selling an estimated $898 and leaving 1 share worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #10357.

UBS Group first reported a position in INTS in Q4 2023 and has held it in 11 quarters since. The position peaked at $78.7K in Q3 2024. 14 funds tracked by Wall St. Rank hold INTS as of Q2 2026.

  • UBS Group held 1 share of Intensity Therapeutics worth $4 as of Q2 2026.
  • UBS Group sold 191 Intensity Therapeutics shares in Q2 2026, an estimated $898.
  • Intensity Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10357 holding.
  • UBS Group first reported a position in Intensity Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • UBS Group's Intensity Therapeutics position peaked at $78.7K in Q3 2024.
  • 14 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.